Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maintenance Bevacizumab vs Continuation of XELOXA in Metastatic Colorectal Cancer
NCT00335595Phase 3Completed
- Sponsor
- Spanish Cooperative Group for Digestive Tumour Therapy
- Start
- Jul 2006
- Primary completion
- Jun 2012
- Modality
- Monoclonal Antibodies, DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors
- Countries
- 1
01
Overview
A Phase 3 trial of bevacizumab, capecitabine, oxaliplatin in colorectal cancer (CRC), sponsored by Spanish Cooperative Group for Digestive Tumour Therapy. Started Jul 2006; status: completed.
02
Drugs
bevacizumabcapecitabineoxaliplatin
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT00335595.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00335595.